News | April 09, 2009

Gene Variant Associated with Diminished Effects of Clopidogrel in PCI Patients After One Year

April 9, 2009 - According to research presented last week at ACC, patients with the CYP2C19*2 genotype had more ischemic events in the one year following percutaneous coronary intervention (PCI).

A study was undertaken to link patients’ non-responsiveness to clopidogrel to the genetic variability of the Cytochrome P450 gene, or CYP2C19. The relation of the CYP2C19*2 variant to platelet function was measured through ADP-induced platelet aggregation and one-year cardiovascular outcomes in 227 patients using clopidogrel following traditional post-PCI procedures used to treat coronary heart disease. It was determined that those patients with the CYP2C19*2 genotype did in fact have more ischemic events in the one year following PCI.

The CYP2C19*2 variant is present in about 30 percent of the general U.S. population.

“This knowledge may enable physicians for the first time to improve individual antiplatelet management by a diagnostic approach utilizing platelet function or genetic testing,” said Paul A. Gurbel, M.D., lead author from the University of Maryland School of Medicine in Baltimore, Maryland. Patients with high platelet reactivity already on clopidogrel therapy may be offered alternative P2Y12 inhibitors that are either not prodrugs or a thienopyridine not highly dependent on CYP2C19 for metabolic activation. Alternatively, prior to institution of clopidogrel therapy, genetic testing may also lead to more selective use of these alternative agents.”

Dr. Gurbel presented the study “Influence of CYP2C19 Polymorphism on Antiplatelet Effects of Clopidogrel and Long-Term Recurrent Ischemic Event Occurrence” during the ACC in Orlando, FL.

For more information: www.acc.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init